主要研究目的：以江苏恩华药业股份有限公司研发、江苏恩华赛德药业有限责任公司生产的盐酸左米那普仑缓释胶囊（规格：120 mg）为受试制剂，以Pierre Fabre Medicament Production生产的盐酸左米那普仑缓释胶囊（商品名：FETZIMA® 规格：120mg，持证商Allergan Sales LLC）为参比制剂，研究两制剂在中国健康成年受试者中于空腹/餐后状态下的吸收速度和吸收程度，评价两制剂间的生物等效性。次要研究目的：评估健康受试者单次空腹/餐后口服盐酸左米那普仑缓释胶囊受试制剂和参比制剂后的安全性。

开始日期2024-11-18

申办/合作机构

江苏恩华药业股份有限公司

CTR20241032

/ TerminatedN/A

盐酸左米那普仑缓释胶囊人体生物等效性试验预试验

主要研究目的：以江苏恩华药业股份有限公司研发、江苏恩华赛德药业有限责任公司生产的盐酸左米那普仑缓释胶囊（规格：120 mg）为受试制剂，以Pierre Fabre Medicament Production生产的盐酸左米那普仑缓释胶囊（商品名：FETZIMA® 规格：120mg，持证商Allergan Sales LLC）为参比制剂，研究两制剂在中国健康成年受试者中于空腹/餐后状态下的吸收速度和吸收程度，初步评价两制剂间的生物等效性，为后期正式试验方案的采血点、样本量等设计提供依据。次要研究目的：评估健康受试者单次空腹/餐后口服盐酸左米那普仑缓释胶囊受试制剂和参比制剂后的安全性。

开始日期2024-04-18

申办/合作机构

江苏恩华药业股份有限公司

NCT03569475

/ Completed临床3期

A Double-blind, Placebo- and Active-controlled Evaluation of the Safety and Efficacy of Levomilnacipran ER in Pediatric Patients 7-17 Years With Major Depressive Disorder

The objective of this study is to evaluate the efficacy, safety, and tolerability of levomilnacipran compared with placebo in pediatric outpatients (7-17 years) with major depressive disorder (MDD).

开始日期2018-07-06

申办/合作机构

Allergan UC

100 项与盐酸左旋体米那普仑相关的临床结果

登录后查看更多信息

100 项与盐酸左旋体米那普仑相关的转化医学

登录后查看更多信息

100 项与盐酸左旋体米那普仑相关的专利（医药）

登录后查看更多信息

174

项与盐酸左旋体米那普仑相关的文献（医药）

2025-06-01·FOOD AND CHEMICAL TOXICOLOGY

Repurposing levomilnacipran to attenuate premature ovarian insufficiency induced by cyclophosphamide in female Wistar albino rats through modulation of TLR4/p38-MAPK/NF-κB p65, caspase-3-driven apoptosis, and Klotho protein expression

Article

作者: Attya, Mina Ezzat ; Khalaf, Marwa M ; Rofaeil, Remon Roshdy ; Abo-Youssef, Amira M ; Hemeida, Ramadan Am ; Sharata, Ehab E

AIM:

This study aims to explore the mitigative impact of levomilnacipran (LVM) against cyclophosphamide (CPA)-induced premature ovarian insufficiency by targeting TLR4/p38 MAPK/NF-κB p65, and klotho expression.

METHODS:

Rats were allocated into five groups as follows: control, LVM, CPA, CPA + LVM, and CPA + TRI. Serum hormones and histopathological examination were performed. To assess oxidative stress, ovarian MDA, GSH, and SOD were evaluated. The ovarian contents of caspase-3 and inflammatory markers were assessed using the ELISA method. The expression of ovarian NF-κB p65 was examined using an immunohistochemical technique. RT-qPCR was used to measure Bax and Bcl-2 mRNA expression. Utilizing a Western blot, the TLR4, p38 MAPK, α-Klotho, and cleaved caspase-3 levels were estimated. The estrous cycle was also monitored.

FINDINGS:

LVM attenuated CPA-induced ovarian toxicity by regulating hormones and alleviating histopathological aberrations. It also raised SOD and GSH levels and lowered MDA's ovarian content. Moreover, Bcl-2 levels were raised, Bax and caspase-3 expression levels were reduced, and IL-18, IL-1β, and TNF-α levels were all reduced. LVM-induced ovarian protection by diminishing TLR4/p38 MAPK/NF-κB p65 expression and boosting the protein levels of α-Klotho.

SIGNIFICANCE:

LVM mitigated POI caused by CPA by downregulating TLR4/p38 MAPK/NF-κB p65, enhancing the α-Klotho level and attenuating caspase-3 derived apoptosis.

2025-05-30·Scientific Reports

CD9, a novel potential biomarker of sarcopenia.

Article

作者: Wang, Xuena ; Lu, Bin ; Bai, Peirong ; Li, Na ; Yin, Lin ; Wu, Shasha

Sarcopenia is defined as a progressive decrease in skeletal muscle mass and strength due to ageing, and is associated with adverse outcomes such as falls, fractures, and physical disability, leading to increased healthcare expenditures and mortality risks. Although sarcopenia has recently become a major challenge, there are currently no effective interventions or drugs marketed for sarcopenia. Therefore, new biomarkers for early diagnosis and targeted drugs for the treatment of sarcopenia are urgently needed. In the present research, transcriptomics and proteomics analyses were combined and experiments at the transcriptional and protein levels were conducted to identify key genes and molecular mechanisms underlying sarcopenia in senescence-accelerated mouse prone 8 (SAM-P8) mice, followed by molecular docking to predict targeted drugs. The combined omics analysis identified 8 key genes, while the experiments verified that only CD9 significantly decreased in sarcopenia. The gene set enrichment analysis (GSEA) results suggested that CD9 involved in ATP biosynthesis, mitochondrial biogenesis, and oxidative phosphorylation. Besides, dapoxetine, levomilnacipran, and milnacipran were predicted to target CD9 through molecular docking. Our study reported for the first time that CD9 is a novel potential biomarker of sarcopenia, and targeting CD9 may be a new idea for the development of therapeutic drugs for sarcopenia.

2025-04-01·INTERNATIONAL IMMUNOPHARMACOLOGY

Levomilnacipran alleviates cyclophosphamide-induced hepatic dysfunction in male Wistar albino rats; emerging role of α-Klotho/TLR4/p38-MAPK/NF-κB p65 and caspase-3-driven apoptosis trajectories

Article

作者: Attya, Mina Ezzat ; Hemeida, Ramadan A M ; Abo-Youssef, Amira M ; Rofaeil, Remon Roshdy ; Sharata, Ehab E ; Khalaf, Marwa M

AIM:

This study aims to investigate the potential protective effect of levomilnacipran (LVM) against cyclophosphamide (CPA)-induced hepatotoxicity by targeting α-Klotho/TLR4/p38-MAPK/NF-κB p65 and Caspase-3-dependent apoptosis signaling pathways.

MAIN METHODS:

The toxicity of CPA was assessed using biochemical analysis of the serum hepatotoxicity parameters (AST, ALT, and direct bilirubin) and histopathological examination. Hepatic MDA and SOD were evaluated. The ELISA procedure was employed to evaluate the levels of hepatic TNF-α, IL-1β, and IL-18, hepatic caspase-3, and serum α-Klotho. The expression of hepatic TLR4 and NF-κB p65 was examined using an immunohistochemical technique. A western blot assay was used to determine the expression of MYD88, and p38-MAPK.

KEY FINDINGS:

LVM abrogated CPA-induced hepatotoxicity by reducing the elevated hepatoxicity markers and mitigating the histopathological aberrations. It also lowered MDA content and increased SOD activity. Furthermore, it reduced TNF-α, IL-1β, and IL-18 contents, as well as caspase-3 activity. Additionally, LVM diminished TLR4, MYD88, NF-κB p65, and p38 MAPK expression and boosted the levels of α-Klotho.

SIGNIFICANCE:

LVM alleviated hepatic injury generated by CPA via downregulating TLR4/p38 MAPK/NF-κB p65 signaling cascade through the participation of α-Klotho, as well as inhibiting caspase-3-driven apoptosis.

项与盐酸左旋体米那普仑相关的新闻（医药）

2025-06-18

·米内网

【聚焦】4亿大品种！华海药业获批了

精彩内容近日，华海药业公告称，公司申报的4类仿制药富马酸喹硫平缓释片获批生产并视同过评，截至目前，公司在该项目上已投入研发费用约1693万元。米内网数据显示，近年来中国三大终端六大市场（统计范围详见本文末）富马酸喹硫平缓释片销售额均超过4亿元。富马酸喹硫平缓释片是一种非典型抗精神病药物，用于治疗精神分裂症和双相情感障碍的抑郁发作。米内网数据显示，近年来中国三大终端六大市场富马酸喹硫平缓释片销售额均超过4亿元。虽然该药已被纳入第四批集采，但市场规模未出现较大幅度下滑。从企业格局看，原研厂家阿斯利康主导市场，但占比呈逐年下滑态势。近年来中国三大终端六大市场富马酸喹硫平缓释片销售情况（单位：万元）来源：米内网格局数据库在神经系统领域，华海药业拥有33个品种的生产批文，其中32个已过评或视同过评，集中在精神安定药（10个）、精神兴奋药（10个）、抗癫痫药（8个）等亚类。其中，托吡酯片、拉莫三嗪片、阿立哌唑片、盐酸多奈哌齐片、盐酸帕罗西汀片、利培酮片等为首家过评。华海药业已过评的神经系统药物来源：米内网一致性评价进度数据库此外，目前华海药业还有7个神经系统药物以新注册分类申报在审，其中甲磺酸沙非胺片、布瑞哌唑片、盐酸卡利拉嗪胶囊、盐酸左米那普仑缓释胶囊等均暂无仿制药获批。华海药业新分类申报在审的神经系统药物来源：米内网中国申报进度（MED）数据库注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至6月18日，如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

一致性评价

2024-11-25

·PRNewswire

Major Depressive Disorder Market to Register Immense Growth by 2034 Owing to a Robust Pipeline | DelveInsight

With the anticipated introduction of new treatments such as COMP360 (COMPASS Pathways), Zuranolone (SAGE Therapeutics/Biogen), LY03005 (Luye Pharma), REL-1017 (Relmada Therapeutics), Seltorexant (Minerva Neurosciences/Janssen Pharmaceutical), ABV-1504 (BioLite/ABVC BioPharma), and other and increasing disease awareness, it's reasonable to expect a significant transformation in the major depressive disorder market in the coming years. LAS VEGAS, Nov. 25, 2024 /PRNewswire/ -- Major depressive disorder (MDD), commonly referred to as depression, is a serious medical condition that affects a person's mood, behavior, thinking, and physical well-being. It is different from the temporary feelings of sadness that everyone experiences and should not be confused with the deep grief following the loss of a loved one. MDD is typically a recurrent and episodic condition, meaning that someone who has experienced depression and recovered is likely to face additional episodes, often within 2 to 3 years. As per DelveInsight analysis, the total diagnosed prevalent cases of MDD in the 7MM were found to be approximately 44 million cases in 2023, which is expected to increase during the forecast period (2024–2034). Among the severity-specific diagnosed prevalent cases of MDD, the highest prevalence was observed in moderate cases accounting for approximately 17 million cases in the 7MM in 2023 followed by severe cases and mild cases. Major depressive disorder can be addressed through several treatment approaches, including pharmacological interventions, psychotherapy, interventional methods, and lifestyle changes. Initial treatment often involves either medication, psychotherapy, or a combination of both, with combined therapy proving more effective than using either alone. For severe cases of major depression, electroconvulsive therapy is the most effective option. The current range of recommended pharmacological treatments for major depressive disorder primarily includes antidepressants such as monoamines, tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), and selective reuptake inhibitors, including medications like VRAYLAR, BRINTELLIX (now TRINTELLIX), SPRAVATO, REXULTI, and FETZIMA. In the upcoming major depressive disorder treatment market landscape, there are a plethora of companies investigating agents for use in major depressive disorder which includes Sage Therapeutics, Relmada Therapeutics, Johnson & Johnson Services, Inc., Biogen, COMPASS Pathways, Luye Pharma, and others. Many more pharma companies are conducting clinical trials for therapies for major depressive disorder. To know more about upcoming major depressive disorder therapies showing positive results, visit @ Drugs for Major Depressive Disorder Treatment DelveInsight estimates that the market size for major depressive disorder is expected to grow from USD 7.1 billion in 2023 with a significant CAGR by 2034. The disease awareness and the emergence of new products in the pipeline will add to the market growth in the future. In addition, persistently rising cases of MDD in the forecast period will contribute to the rise in the MDD treatment market. The current pipeline for major depressive disorder includes a range of drugs with diverse mechanisms of action (MoA). COMP360 (COMPASS Pathways) , Zuranolone (SAGE Therapeutics/Biogen) , LY03005 (Luye Pharma) , REL-1017 (Relmada Therapeutics) , seltorexant (Minerva Neurosciences/Janssen Pharmaceutical) , ABV-1504 (BioLite/ABVC BioPharma), and some others are the most promising drugs of this indication. Ongoing research and current trials have the potential to change the MDD market. Keen to know how the MDD market will evolve by 2034? Find out @ Major Depressive Disorder Market Report The potential for effective major depressive disorder treatment in the future is expected to grow with the addition of numerous drugs to the pipeline of new therapeutics. Currently, a variety of candidate drugs for the treatment of major depressive disorder are being tested in various clinical trials, with some showing positive results. Any drug approved with increased safety and efficacy is expected to cause significant changes in the overall major depressive disorder market. Now, let's examine the pipeline therapies under investigation for major depressive disorder COMP360: COMPASS Pathways Phase III COMPASS Pathways is investigating the use of its experimental psilocybin therapy, COMP360, for treating serious mental health conditions like major depressive disorder. COMP360 is a synthesized version of psilocybin, the active compound found in certain "magic mushrooms," and is administered alongside psychological support. Psilocybin has shown promise in therapeutic applications, and COMP360 has been granted Breakthrough Therapy status by the US FDA as well as an Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression (TRD). Currently, COMPASS Pathways is running a Phase II trial for MDD, with a Phase III trial underway in partnership with Massachusetts General Hospital to further explore its potential in meeting mental health treatment needs. The company is anticipated to release top-line data from two key trials, COMP005 and COMP006, by the fourth quarter of 2024 and mid-2025, respectively, for the treatment of TRD. Zuranolone: SAGE Therapeutics/Biogen Phase III Zuranolone, being developed by SAGE Therapeutics and Biogen, is a next-generation oral, highly potent, and selective positive allosteric modulator, designed for specific targeting of synaptic and extrasynaptic GABAA receptors. The binding sites for neuroactive steroids (NASs) are different from those for GABA, benzodiazepines, and barbiturates. The GABA system, which is the primary inhibitory signaling pathway in the brain and central nervous system (CNS), plays a key role in regulating CNS function. SAGE-217 is currently in phase III clinical development for major depressive disorder and is being evaluated through the LANDSCAPE and NEST clinical trial programs, which include multiple studies involving thousands of participants, with varying dosing regimens, clinical endpoints, and treatment approaches. In February 2023, the US FDA accepted the New Drug Application (NDA) for zuranolone in the treatment of MDD. However, in August 2023, the FDA issued a Complete Response Letter (CRL) regarding the NDA for zuranolone for treating adults with MDD. Sage and Biogen are now assessing the feedback and determining their next steps. LY03005: Luye Pharma LY03005, developed by Luye Pharma, is one of the company's key products in the CNS therapeutic space. It is their exclusive extended-release tablet formulation of ansofaxine hydrochloride, a serotonin-norepinephrine-dopamine triple reuptake inhibitor (SNDRI) designed for treating major depressive disorder. LY03005 aims to offer improved efficacy and fewer side effects compared to conventional antidepressants like SSRIs and SNRIs. Ansofaxine, a prodrug of desvenlafaxine, strongly inhibits dopamine reuptake in addition to serotonin and norepinephrine, demonstrating superior efficacy in clinical trials. In March 2020, the US FDA accepted the NDA submission for LY03005, which is currently in Phase III pivotal clinical trials for MDD treatment. Seltorexant: Minerva Neurosciences/Janssen Pharmaceutical Phase III Seltorexant, developed by Minerva Neurosciences and Janssen Pharmaceutical, is a selective orexin-2 receptor antagonist intended as an adjunctive treatment for major depressive disorder and for managing insomnia. It is the most advanced ORX2-specific molecule in clinical development, acting as an antagonist by binding to its receptor. Seltorexant is being studied for two main uses: insomnia without psychiatric disorders and MDD in patients who do not respond adequately to SSRIs or SNRIs. In May 2024, Johnson & Johnson reported positive topline results from the pivotal Phase III MDD3001 trial, which assessed its efficacy and safety as an add-on therapy to antidepressants in adults and elderly MDD patients. Discover which therapies are expected to grab major MDD market share @ New Treatments for Major Depressive Disorder REL-1017: Relmada Therapeutics Phase III REL-1017, being developed by Relmada Therapeutics, is a novel chemical entity (NCE) and an NMDA receptor (NMDAR) channel blocker that specifically targets overactive channels while preserving normal glutamatergic neurotransmission. The U.S. FDA has granted it Fast Track Designation as an immunotherapy for treating major depressive disorder. In a Phase II trial, REL-1017 exhibited rapid, strong, and lasting antidepressant effects, with statistically significant improvements over placebo in depression measures. The study also indicated a favorable safety, tolerability, and pharmacokinetic profile for the drug. Currently, it is in late-stage development for MDD, being tested in Phase III trials for both adjunctive and monotherapy. In June 2024, Relmada published clinical data from the Reliance I Study. The company is actively enrolling patients in ongoing trials for REL-1017, including Reliance II (Study 302), with top-line results expected in the latter half of 2024, and Relight (Study 304), which is anticipated to provide results about six months after the completion of Study 302. ABV-1504: ABVC BioPharma Phase II ABV-1504, developed by ABVC BioPharma, features PDC-1421 as its active ingredient and is classified as a botanical investigational new drug. Through its subsidiary BioLite, ABVC has completed a Phase II trial of ABV-1504, a botanical Norepinephrine Transporter (NET) inhibitor. This trial, conducted at Stanford University, showed that the PDC-1421 capsule was safe and well-tolerated among six enrolled adult patients. Both low and high doses of PDC-1421 successfully achieved the study's primary endpoints, showing a necessary 40% improvement in ADHD-RS-IV test scores. In April 2023, PDC-1421 was awarded a US patent (US 11,554,154 B2) for the treatment of Major Depressive Disorder (MDD). The drug has also completed a Phase II trial in MDD patients, and the company intends to hold an End of Phase II (EOP II) meeting with the FDA in the near future. Itruvone (PH10): VistaGen Therapeutics Phase II Itruvone (PH10), being developed by VistaGen Therapeutics, is an investigational first-in-class synthetic neurosteroid that is odorless and fast-acting, showing promise for various neuropsychiatric conditions related to depression and suicidal thoughts. VistaGen is focusing on PH10 as a potential quick-acting, non-sedating, and non-addictive treatment for MDD that patients can conveniently self-administer at home. When self-administered, a microgram-level dose of PH10 sprayed into the nose interacts with nasal chemosensory receptors, activating brain neural circuits to produce rapid antidepressant effects without the side effects, systemic exposure, or safety issues associated with FDA-approved treatments for MDD, such as oral antidepressants and esketamine. After successfully completing Phase IIa trials for MDD, VistaGen is now gearing up for the planned Phase IIb clinical development of PH10 for this condition. Moreover, in December 2022, PH10 received fast-track designation from the US FDA. LPCN 1154: Lipocine Phase II LPCN 1154, developed by Lipocine, is an oral formulation of brexanolone designed for rapid relief of postpartum depression. Its active ingredient is a naturally occurring positive allosteric modulator of the GABAa receptor. This medication is intended to provide an "at-home" treatment option, making it more accessible than the current standard care, which involves invasive procedures and hospitalization. In September 2022, the FDA approved Lipocine's proposal to demonstrate the efficacy of LPCN 1154 through a single pivotal pharmacokinetic bridge to the approved IV infusion of brexanolone via a 505(b)(2) NDA submission. In June 2024, Lipocine announced positive topline results from a pivotal pharmacokinetic study, confirming that LPCN 1154 is bioequivalent to IV brexanolone for PPD treatment. Lipocine aims to submit the NDA by the end of the fourth quarter of 2024. Discover more about drugs for major depressive disorder in development @ Major Depressive Disorder Clinical Trials DelveInsight's latest published market report titled as Major Depressive Disorder Market Insight, Epidemiology, and Market Forecast – 2034 will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the major depressive disorder country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market's underlying potential. The major depressive disorder market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Diagnosed Prevalent Cases of MDD Gender-specific Diagnosed Prevalent Cases of MDD Severity-specific Diagnosed Prevalent Cases of MDD The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM major depressive disorder market. Highlights include: 11-year Forecast 7MM Analysis Epidemiology-based Market Forecasting Historical and Forecasted Market Analysis upto 2034 Emerging Drug Market Uptake Peak Sales Analysis Key Cross Competition Analysis Industry Expert's Opinion Access and Reimbursement Download this major depressive disorder market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the major depressive disorder market. Also, stay abreast of the mitigating factors to improve your market position in the major depressive disorder therapeutic space. Related Reports Major Depressive Disorder Pipeline Major Depressive Disorder Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key major depressive disorder companies, including GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research & Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals, among others. Treatment-Resistant Depression Market Treatment-Resistant Depression Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key TRD companies, including Navitor Pharmaceuticals, Supernus Pharmaceuti, Novartis, Relmada Therapeutics, Beckley Psytech, COMPASS Pathways, Axsome Therapeutics, Celon Pharma, among others. Treatment-Resistant Depression Pipeline Treatment-Resistant Depression Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key treatment-resistant depression companies, including Axsome Therapeutics, COMPASS Pathways, Merck Sharp & Dohme Corp., Navitor Pharmaceuticals, Inc., Taisho Pharmaceutical Co., Ltd., GH Research Limited, Novartis Pharmaceuticals, Reckitt Benckiser LLC, Relmada Therapeutics, Inc., SAGE Therapeutics, Navitor Pharmaceuticals, Sumitomo Dainippon Pharma, Alkermes, AbbVie, Janssen Pharmaceuticals, Celon Pharma, ACADIA Pharmaceuticals, Pherin Pharmaceuticals, ATAI Life Sciences, among others. Postpartum Depression Market Postpartum Depression Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key postpartum depression companies, including Sage Therapeutics, Epharmix, Inc., among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床2期临床3期临床结果快速通道突破性疗法

2024-07-15

·信狐药迅

正大天晴 JAK/ROCK抑制剂罗伐昔替尼；5个潜在3类、4类首仿品种提交上市申请，看看谁家品种？|新受理（7.8-7.14）

本周药品注册受理数据，分门别类呈现，一目了然。(7.8-7.14）新药上市申请药品名称企业注册分类受理号TQ05105片正大天晴药业集团股份有限公司1CXHS2400053苯胺洛芬注射液石家庄以岭药业股份有限公司1CXHS2400052布瑞哌唑口溶膜四川科伦药业股份有限公司2.2CXHS2400051布瑞哌唑口溶膜四川科伦药业股份有限公司2.2CXHS2400050重组红细胞生成刺激蛋白注射液(CHO细胞)沈阳三生制药有限责任公司1CXSS2400064塞多明基注射液北京诺思兰德生物技术股份有限公司1CXSS2400066索卡佐利单抗注射液兆科(广州)肿瘤药物有限公司2.2CXSS2400065 新药临床申请药品名称企业注册分类受理号注射用亚胺培南西司他丁钠福诺巴坦苏州信诺维医药科技股份有限公司1CXHL2400709RZ-629片宁康瑞珠生物制药(珠海)有限公司1CXHL2400708RZ-629片宁康瑞珠生物制药(珠海)有限公司1CXHL2400707H018软膏江苏柯菲平医药股份有限公司1CXHL2400705H018软膏江苏柯菲平医药股份有限公司1CXHL2400704H018软膏江苏柯菲平医药股份有限公司1CXHL2400703HSK21542注射液辽宁海思科制药有限公司1CXHL2400710SIGX1094R片希格生科(深圳)有限公司1CXHL2400697SIGX1094R片希格生科(深圳)有限公司1CXHL2400696注射用Pt(0506)101北京硕佰医药科技有限责任公司1CXHL2400695VSA003注射液维亚臻生物技术(苏州)有限公司1CXHL2400694SIR9900片维泰瑞隆(北京)生物科技有限公司1CXHL2400700SIR9900片维泰瑞隆(北京)生物科技有限公司1CXHL2400699SIR9900片维泰瑞隆(北京)生物科技有限公司1CXHL2400698SPH4336片上海医药集团股份有限公司1CXHL240069118F-LNC1007注射液烟台蓝纳成生物技术有限公司1CXHL2400682ICP-248片北京诺诚健华医药科技有限公司1CXHL2400693ICP-248片北京诺诚健华医药科技有限公司1CXHL2400692JAB-23E73片北京加科思新药研发有限公司1CXHL2400689JAB-23E73片北京加科思新药研发有限公司1CXHL2400688JAB-23E73片北京加科思新药研发有限公司1CXHL2400687WJ47156片上海君实生物医药科技股份有限公司1CXHL2400680WJ47156片上海君实生物医药科技股份有限公司1CXHL2400678CFT8919胶囊贝达药业股份有限公司1CXHL2400677CFT8919胶囊贝达药业股份有限公司1CXHL2400676ENC0653软膏轶诺(浙江)药业有限公司1CXHL2400664ENC0653软膏轶诺(浙江)药业有限公司1CXHL2400674ENC0653软膏轶诺(浙江)药业有限公司1CXHL2400673ENC0653软膏轶诺(浙江)药业有限公司1CXHL2400672ENC0653软膏轶诺(浙江)药业有限公司1CXHL2400671ENC0653软膏轶诺(浙江)药业有限公司1CXHL2400670ENC0653软膏轶诺(浙江)药业有限公司1CXHL2400669ENC0653软膏轶诺(浙江)药业有限公司1CXHL2400668ENC0653软膏轶诺(浙江)药业有限公司1CXHL2400667ENC0653软膏轶诺(浙江)药业有限公司1CXHL2400666HMPL-760胶囊和记黄埔医药(上海)有限公司1CXHL2400665TDI01混悬液北京泰德制药股份有限公司1CXHL2400663HBW-004285片成都海博为药业有限公司1CXHL2400662注射用NC527-X浙江海擘生物科技有限公司1CXHL2400661JC242片北京佳诚生物医药科技开发有限公司2.1CXHL2400706醋酸锌直服颗粒北京科信必成医药科技发展有限公司2.2CXHL2400702醋酸锌直服颗粒北京科信必成医药科技发展有限公司2.2CXHL2400701QLM2014齐鲁制药有限公司2.2CXHL2400679司美格鲁肽注射液江苏诺泰澳赛诺生物制药股份有限公司2.2CXHL2400686司美格鲁肽注射液江苏诺泰澳赛诺生物制药股份有限公司2.2CXHL2400685司美格鲁肽注射液江苏诺泰澳赛诺生物制药股份有限公司2.2CXHL2400684司美格鲁肽注射液江苏诺泰澳赛诺生物制药股份有限公司2.2CXHL2400683HKG-215合肥柏安医药科技有限公司2.3CXHL2400690缬沙坦马来酸左氨氯地平片石药集团中奇制药技术(石家庄)有限公司2.3CXHL2400675叶酸片北京斯利安药业有限公司2.4CXHL2400681IPM001注射液北京臻知医学科技有限责任公司1CXSL2400447IX001 TCR-T注射液上海镔铁生物科技有限责任公司1CXSL2400446IX001 TCR-T注射液上海镔铁生物科技有限责任公司1CXSL2400445注射用PRO1286普方生物制药(苏州)有限公司1CXSL2400443TQB2253注射液正大天晴药业集团南京顺欣制药有限公司1CXSL2400448SHR-1905注射液广东恒瑞医药有限公司1CXSL2400442IBR900细胞注射液英百瑞(杭州)生物医药有限公司1CXSL2400441SK08活菌散广州知易生物科技有限公司1CXSL2400440CM380康诺亚生物医药科技(成都)有限公司1CXSL2400439TQH2722注射液正大天晴药业集团南京顺欣制药有限公司1CXSL2400437注射用CMDE005浙江时迈药业有限公司1CXSL2400438SCTB35注射液神州细胞工程有限公司1CXSL2400435 仿制药申请药品名称企业注册分类受理号利多卡因丁卡因乳膏科笛生物医药(无锡)有限公司3CYHS2402174尼麦角林片海南斯达制药有限公司3CYHS2402142注射用氢化可的松琥珀酸钠江苏江丰医药科技有限公司3CYHS2402154维生素B12注射液江苏宝东医药科技有限公司3CYHS2402153硫代硫酸钠注射液山东齐都药业有限公司3CYHS2402152硫代硫酸钠注射液山东齐都药业有限公司3CYHS2402151卡络磺钠注射液广州一品红制药有限公司3CYHS2402150阿仑膦酸钠口服溶液苏州华健瑞达医药技术有限公司3CYHS2402149恩那度司他片深圳信立泰药业股份有限公司3CYHS2402145恩那度司他片深圳信立泰药业股份有限公司3CYHS2402144恩那度司他片深圳信立泰药业股份有限公司3CYHS2402143米诺地尔搽剂广州绿十字制药股份有限公司3CYHS2402141米诺地尔搽剂广州绿十字制药股份有限公司3CYHS2402140盐酸普罗帕酮注射液海南慧通生物医药科技有限公司3CYHS2402138盐酸普罗帕酮注射液海南慧通生物医药科技有限公司3CYHS2402137盐酸罗匹尼罗片江苏和晨药业有限公司3CYHS2402136地塞米松磷酸钠注射液安徽美来药业股份有限公司3CYHS2402133门冬氨酸钾镁注射液山东华鲁制药有限公司3CYHS2402129注射用比阿培南悦康药业集团股份有限公司3CYHS2402162西格列汀二甲双胍缓释片河南中杰药业有限公司3CYHS2402158西格列汀二甲双胍缓释片河南中杰药业有限公司3CYHS2402157己酮可可碱缓释片河北一品生物医药有限公司3CYHS2402127米诺地尔搽剂江西海尔思药业股份有限公司3CYHS2402125氟比洛芬酯注射液重庆药友制药有限责任公司3CYHS2402099依巴斯汀口服溶液浙江易泽达医药科技有限公司3CYHS2402101氯化钾注射液江苏华阳制药有限公司3CYHS2402100钠钾镁钙注射用浓溶液山东方明药业集团股份有限公司3CYHS2402098巴氯芬注射液南京海纳医药科技股份有限公司3CYHS2402094巴氯芬注射液南京海纳医药科技股份有限公司3CYHS2402093巴氯芬注射液南京海纳医药科技股份有限公司3CYHS2402092巴氯芬注射液南京海纳医药科技股份有限公司3CYHS2402091重酒石酸去甲肾上腺素注射液湖南华纳大药厂股份有限公司3CYHS2402087复方醋酸钠林格注射液安徽丰原药业股份有限公司3CYHS2402119复方醋酸钠林格注射液安徽丰原药业股份有限公司3CYHS2402118法莫替丁注射液海南慧通生物医药科技有限公司3CYHS2402117硫代硫酸钠注射液重庆凯林制药有限公司3CYHS2402108硫代硫酸钠注射液重庆凯林制药有限公司3CYHS2402107盐酸普罗帕酮注射液石家庄四药有限公司3CYHS2402115奥沙利铂注射液华夏生生药业(北京)有限公司3CYHS2402086奥沙利铂注射液华夏生生药业(北京)有限公司3CYHS2402085奥沙利铂注射液华夏生生药业(北京)有限公司3CYHS2402084硫代硫酸钠注射液华夏生生药业(北京)有限公司3CYHS2402069缩宫素注射液江西泰吉立生物医药科技有限公司3CYHS2402068注射用盐酸罗沙替丁醋酸酯沈阳新马药业有限公司3CYHS2402066硝普钠注射液重庆药友制药有限责任公司3CYHS2402082布瑞哌唑口腔崩解片湖南科伦制药有限公司3CYHS2402079布瑞哌唑口腔崩解片湖南科伦制药有限公司3CYHS2402078盐酸纳洛酮注射液海南普利制药股份有限公司3CYHS2402071盐酸纳洛酮注射液海南普利制药股份有限公司3CYHS2402070阿仑膦酸钠口服溶液湖南普道医药技术有限公司3CYHS2402058复合磷酸氢钾注射液石家庄迪斯凯威医药科技有限公司3CYHS2402065米诺地尔搽剂武汉华尔生物科技有限公司3CYHS2402064米诺地尔搽剂河北义海医药科技有限公司3CYHS2402063米诺地尔搽剂河北义海医药科技有限公司3CYHS2402062维生素B6注射液济川药业集团有限公司3CYHS2402061盐酸阿莫罗芬搽剂景时(杭州)药业有限公司4CYHS2402175达格列净二甲双胍缓释片南京汉欣医药科技有限公司4CYHS2402173阿卡波糖片福建省宝诺医药研发有限公司4CYHS2402172左氧氟沙星滴眼液珠海联邦制药股份有限公司中山分公司4CYHS2402171维生素B12滴眼液珠海同源药业有限公司4CYHS2402170乙酰半胱氨酸泡腾片浙江领创优品药业有限公司4CYHS2402169二甲双胍恩格列净片(I)广州仁恒医药科技股份有限公司4CYHS2402168二甲双胍恩格列净片(V)广州仁恒医药科技股份有限公司4CYHS2402167二甲双胍恩格列净片(VI)广州仁恒医药科技股份有限公司4CYHS2402166左卡尼汀注射液海南卓科制药有限公司4CYHS2402155氧(液态)浙江中龙气体科技有限公司4CYHS2402148丙酸氟替卡松鼻喷雾剂齐鲁制药有限公司4CYHS2402147双氯芬酸钠肠溶片浙江昂利康制药股份有限公司4CYHS2402146他达拉非片白云山东泰商丘药业有限公司4CYHS2402139左氧氟沙星滴眼液石家庄四药有限公司4CYHS2402135亚叶酸钙注射液泽田(山东)药业有限公司4CYHS2402134布瑞哌唑片西安远大科创医药科技有限公司4CYHS2402132布瑞哌唑片西安远大科创医药科技有限公司4CYHS2402131他达拉非片四川益生智同医药生物科技发展有限公司4CYHS2402130硫酸氨基葡萄糖胶囊北京华睿鼎信科技有限公司4CYHS2402165培哚普利氨氯地平片(III)远大医药(中国)有限公司4CYHS2402164双氯芬酸钠双释放肠溶胶囊北京福元医药股份有限公司4CYHS2402163二甲硅油乳剂山东齐都药业有限公司4CYHS2402161二甲硅油乳剂山东齐都药业有限公司4CYHS2402160二甲硅油乳剂山东齐都药业有限公司4CYHS2402159夫西地酸乳膏湖北科益药业股份有限公司4CYHS2402156恩格列净片康臣药业(内蒙古)有限责任公司4CYHS2402128碳酸镧咀嚼片浙江中同药业有限公司4CYHS2402126阿昔莫司胶囊浙江恒研医药科技有限公司4CYHS2402123沙格列汀二甲双胍缓释片北京康而福药业有限责任公司4CYHS2402122沙格列汀二甲双胍缓释片北京康而福药业有限责任公司4CYHS2402121熊去氧胆酸胶囊海南斯达制药有限公司4CYHS2402120硫酸氨基葡萄糖胶囊通化万通药业股份有限公司4CYHS2402124注射用头孢呋辛钠成都倍特药业股份有限公司4CYHS2402113注射用头孢呋辛钠成都倍特药业股份有限公司4CYHS2402112注射用阿糖胞苷山西铭羽生物科技有限公司4CYHS2402111依折麦布阿托伐他汀钙片(II)乐普制药科技有限公司4CYHS2402110注射用唑来膦酸浓溶液海南葫芦娃药业集团股份有限公司4CYHS2402109来特莫韦注射液山东诚创蓝海医药科技有限公司4CYHS2402106盐酸奥布卡因滴眼液浙江莎普爱思药业股份有限公司4CYHS2402105苯磺顺阿曲库铵注射液山东威智百科药业有限公司4CYHS2402104盐酸氨溴索注射液上海现代哈森(商丘)药业有限公司4CYHS2402090苯磺酸左氨氯地平片石家庄四药有限公司4CYHS2402089苯磺酸左氨氯地平片石家庄四药有限公司4CYHS2402088铝碳酸镁咀嚼片白云山汤阴东泰药业有限责任公司4CYHS2402116乳酸钠林格注射液成都医路康医学技术服务有限公司4CYHS2402114恩格列净片江苏康缘药业股份有限公司4CYHS2402096恩格列净片江苏康缘药业股份有限公司4CYHS2402095布瑞哌唑片湖南科伦制药有限公司4CYHS2402103布瑞哌唑片湖南科伦制药有限公司4CYHS2402102二甲硅油乳剂浙江恒研医药科技有限公司4CYHS2402097盐酸阿罗洛尔片成都苑东生物制药股份有限公司4CYHS2402067替米沙坦氨氯地平片苏州中化药品工业有限公司4CYHS2402083雌二醇片/雌二醇地屈孕酮片复合包装扬州奥锐特药业有限公司4CYHS2402081雌二醇片/雌二醇地屈孕酮片复合包装扬州奥锐特药业有限公司4CYHS2402080富马酸伏诺拉生片杭州煌森生物科技有限公司4CYHS2402077盐酸莫西沙星片哈尔滨珍宝制药有限公司4CYHS2402076富马酸伏诺拉生片湖南千金湘江药业股份有限公司4CYHS2402075富马酸伏诺拉生片湖南千金湘江药业股份有限公司4CYHS2402074非那雄胺片四川依科制药有限公司4CYHS2402073替勃龙片长春金赛药业有限责任公司4CYHS2402072碘克沙醇注射液重庆药友制药有限责任公司4CYHS2402060碘克沙醇注射液重庆药友制药有限责任公司4CYHS2402059注射用盐酸兰地洛尔海南合瑞制药股份有限公司3CYHL2400147甘露醇山梨醇注射液山东齐都药业有限公司3CYHL2400145氟[18F]美他酚注射液天津恒瑞医药有限公司3CYHL2400142阿齐沙坦片江西施美药业股份有限公司3CYHL2400144盐酸左米那普仑缓释胶囊浙江华海药业股份有限公司3CYHL2400141盐酸左米那普仑缓释胶囊浙江华海药业股份有限公司3CYHL2400140盐酸左米那普仑缓释胶囊浙江华海药业股份有限公司3CYHL2400139布洛肾素片山东新华制药股份有限公司3CYHL2400138酒石酸匹莫范色林胶囊武汉人福药业有限责任公司3CYHL2400137注射用伏立康唑天津力生制药股份有限公司4CYHL2400146噻托溴铵吸入粉雾剂南京力成药业有限公司4CYHL2400143盐酸伊立替康脂质体注射液西安力邦制药有限公司4CYHL2400136皮下注射人免疫球蛋白四川远大蜀阳药业有限责任公司3.2CXSL2400434SAL023注射液信立泰(成都)生物技术有限公司3.3CXSL2400444德谷胰岛素利拉鲁肽注射液正大天晴药业集团股份有限公司3.3CXSL2400436 进口申请药品名称企业注册分类受理号伊匹木单抗注射液Bristol-Myers Squibb Pharma EEIG2.2JXSS2400056伊匹木单抗注射液Bristol-Myers Squibb Pharma EEIG2.2JXSS2400055盐酸左西替利嗪口服溶液BRIGHT FUTURE PHARMACEUTICAL LABORATORIES LIMITED5.2JYHS2400036Bomedemstat胶囊Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.1JXHL2400176Bomedemstat胶囊Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.1JXHL2400175Bomedemstat胶囊Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.1JXHL2400174Bomedemstat胶囊Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.1JXHL2400173BI 1839100 片Boehringer Ingelheim International GmbH1JXHL2400171TAK-861片Takeda Development Center Americas,Inc.1JXHL2400180TAK-861片Takeda Development Center Americas,Inc.1JXHL2400179TAK-861片Takeda Development Center Americas,Inc.1JXHL2400178TAK-861片Takeda Development Center Americas,Inc.1JXHL2400177BAY 2862789片Bayer AG1JXHL2400168BAY 2862789片Bayer AG1JXHL2400167PF-06821497片Pfizer Inc.1JXHL2400166PF-06821497片Pfizer Inc.1JXHL2400165罗氟司特乳膏Arcutis Biotherapeutics INC2.4JXHL2400172Elacestrant片Stemline Therapeutics, Inc.5.1JXHL2400170Elacestrant片Stemline Therapeutics, Inc.5.1JXHL2400169MK-3475A注射液Merck Sharp & Dohme LLC1JXSL2400121CSL300 (Clazakizumab)CSL Behring LLC1JXSL2400120艾加莫德α注射液argenx BV2.2JXSL2400122度普利尤单抗注射液Sanofi Winthrop Industrie3.1JXSL2400123 中药相关申请药品名称企业注册分类受理号温经汤颗粒上海医药集团青岛国风药业股份有限公司3.1CXZS2400026SY617嘉亨(珠海横琴)医药科技有限公司1.1CXZL2400038 注：绿色字体部分为潜在首仿品种；不包含原料药、医用氧、注射用水、氯化钠或葡萄糖注射液等申请，不包含再注册、一次性进口、技术转移、复审申请。

申请上市

100 项与盐酸左旋体米那普仑相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10133	盐酸左旋体米那普仑	N06AX	DB08918

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
重度抑郁症	美国	AbbVie, Inc.	2013-07-25

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性缺血性卒中	临床3期	比利时	Pierre Fabre Medicament Information	2012-07-01
急性缺血性卒中	临床3期	捷克	Pierre Fabre Medicament Information	2012-07-01
急性缺血性卒中	临床3期	法国	Pierre Fabre Medicament Information	2012-07-01
急性缺血性卒中	临床3期	德国	Pierre Fabre Medicament Information	2012-07-01
急性缺血性卒中	临床3期	匈牙利	Pierre Fabre Medicament Information	2012-07-01
急性缺血性卒中	临床3期	意大利	Pierre Fabre Medicament Information	2012-07-01
急性缺血性卒中	临床3期	葡萄牙	Pierre Fabre Medicament Information	2012-07-01
急性缺血性卒中	临床3期	俄罗斯	Pierre Fabre Medicament Information	2012-07-01
急性缺血性卒中	临床3期	西班牙	Pierre Fabre Medicament Information	2012-07-01
急性缺血性卒中	临床3期	瑞典	Pierre Fabre Medicament Information	2012-07-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02265367 (CTgov)	N/A	烟草依赖	56	Placebo+Levomilnacipran (Levomilnacipran)	壓範築獵構積襯窪壓蓋(膚齋網鹹範淵衊襯壓獵) = 壓糧膚積範廠齋窪鹹觸獵選構膚鏇鑰遞積鹹遞 (夢艱簾製餘鹽構網觸遞, 6.7) 更多	-	2022-04-22
				Placebo+Levomilnacipran (Placebo)	壓範築獵構積襯窪壓蓋(膚齋網鹹範淵衊襯壓獵) = 顧餘積餘餘遞遞願廠選獵選構膚鏇鑰遞積鹹遞 (夢艱簾製餘鹽構網觸遞, 6.5) 更多
NCT03569475 (CTgov)	临床3期	重度抑郁症	501	Placebo (Placebo)	獵範構衊鑰簾鑰鬱衊壓(鏇餘繭繭繭壓餘襯壓廠) = 鏇鏇齋鹽淵範夢鹽膚範選餘鑰襯鏇齋繭鹹簾繭 (襯鬱鹹壓範糧製鑰鏇鬱, 1.01) 更多	-	2022-03-25
				Levomilnacipran ER (Levomilnacipran ER 40-80 mg/Day)	獵範構衊鑰簾鑰鬱衊壓(鏇餘繭繭繭壓餘襯壓廠) = 築獵襯壓夢襯壓餘窪觸選餘鑰襯鏇齋繭鹹簾繭 (襯鬱鹹壓範糧製鑰鏇鬱, 1.01) 更多
NCT02431806 (CTgov)	临床3期	重度抑郁症	552	Placebo	齋觸願齋鏇獵鹽遞網願(鏇鑰齋觸築醖蓋窪觸獵) = 窪鏇網網齋淵憲簾鹹製選鏇淵膚鏇繭網鏇餘構 (網衊製製衊夢壓鹹範糧, 1.09) 更多	-	2020-09-07
NCT01085812 (CTgov)	临床3期	重度抑郁症	734	placebo (Placebo)	觸淵醖淵製衊膚鏇憲範(顧夢積醖顧簾觸淵鬱鬱) = 蓋廠壓觸壓選鹽糧齋構廠襯鹹選蓋觸願範壓簾 (衊餘壓窪窪製餘襯繭艱, NA)	-	2020-01-13
				Levomilnacipran (Levomilnacipran ER)	觸淵醖淵製衊膚鏇憲範(顧夢積醖顧簾觸淵鬱鬱) = 鹽衊餘夢廠願鑰淵網糧廠襯鹹選蓋觸願範壓簾 (衊餘壓窪窪製餘襯繭艱, NA)
NCT02720198 (CTgov)	临床3期	重度抑郁症	60	Levomilnacipran (Levomilnacipran)	簾膚蓋顧糧顧鬱夢築觸(積簾願糧憲選顧顧壓遞) = 窪襯淵窪獵選衊窪繭鹽蓋膚鹽獵願憲網艱構鹽 (積顧襯鬱醖夢醖壓夢鹹, 6.080) 更多	-	2019-07-02
				Quetiapine (Quetiapine)	簾膚蓋顧糧顧鬱夢築觸(積簾願糧憲選顧顧壓遞) = 衊鑰製夢築鑰膚願夢築蓋膚鹽獵願憲網艱構鹽 (積顧襯鬱醖夢醖壓夢鹹, 7.632) 更多
NCT02466958 (LMIL, CTgov)	临床4期	重度抑郁症	29	levomilnacipran (Levomilnacipran (FETZIMA))	鏇艱膚選衊蓋積鏇範糧(觸壓鏇觸醖壓膚壓衊艱) = 夢鹽鹽製壓醖蓋繭構積艱蓋齋襯鬱鹽鹽憲鹹窪 (鏇繭窪憲襯築製鹹壓築, 2.5) 更多	-	2019-04-26
				Placebo (Placebo)	鏇艱膚選衊蓋積鏇範糧(觸壓鏇觸醖壓膚壓衊艱) = 顧廠構鏇齋鹹窪製築醖艱蓋齋襯鬱鹽鹽憲鹹窪 (鏇繭窪憲襯築製鹹壓築, 2.6) 更多
NCT02288325 (CTgov)	临床4期	重度抑郁症	644	Placebo (Double-Blind Placebo)	壓鏇鹽糧蓋築觸鏇構醖(觸齋製鹹鏇鏇鬱衊夢膚) = 選鹽範網壓遞鏇糧鬱構願選夢網艱願繭鏇簾鏇 (築襯廠夢餘顧簾襯壓鏇, 窪積鹽製蓋鹽遞積鏇構 ~ 衊遞夢願積醖願壓繭築) 更多	-	2018-10-29
				Levomilnacipran ER (Double-Blind FETZIMA®)	壓鏇鹽糧蓋築觸鏇構醖(觸齋製鹹鏇鏇鬱衊夢膚) = 鹽鬱膚衊鹹積範淵顧範願選夢網艱願繭鏇簾鏇 (築襯廠夢餘顧簾襯壓鏇, 顧夢窪簾選顧衊顧艱襯 ~ 鹽醖鏇鑰簾夢憲糧膚願) 更多
NCT01254305 (CTgov)	临床2期	疲劳 \| 重度抑郁症	262	placebo (Placebo)	憲築夢網夢製選艱顧繭(壓遞簾艱積淵醖艱範鏇) = 遞鑰醖鹹繭壓選鏇遞願醖遞夢糧醖艱鏇積築積 (鏇衊鏇夢醖醖鹽鑰醖築, 1.3) 更多	-	2014-08-06
				Levomilnacipran (Levomilnacipran ER)	憲築夢網夢製選艱顧繭(壓遞簾艱積淵醖艱範鏇) = 鏇製淵壓製鏇鏇餘鏇憲醖遞夢糧醖艱鏇積築積 (鏇衊鏇夢醖醖鹽鑰醖築, 1.4) 更多
NCT00969150 (Pubmed)	临床3期	重度抑郁症	362	Levomilnacipran ER 40-120 mg/day	鏇鑰製壓網選鑰艱艱顧(鑰壓醖夢鹹積顧觸壓製) = More levomilnacipran ER patients vs placebo reported AEs; the most common AEs for levomilnacipran ER were nausea (17%) and headache (16%) 憲製遞繭鬱顧築糧窪鏇 (淵艱窪獵醖遞網膚顧糧 ) 更多	不佳	2014-01-01
				Placebo
NCT01377194 (CTgov)	临床3期	重度抑郁症	568	placebo (Placebo)	鏇積築夢齋遞遞壓夢蓋(願觸網製壓觸積鹹繭築) = 製壓觸膚廠膚醖願範願鏇壓憲獵遞蓋壓餘鏇鏇 (齋憲選夢醖鏇繭鏇繭願, 0.77) 更多	-	2013-10-29
				Levomilnacipran (Levomilnacipran ER 40 mg)	鏇積築夢齋遞遞壓夢蓋(願觸網製壓觸積鹹繭築) = 餘齋夢廠選網簾遞糧餘鏇壓憲獵遞蓋壓餘鏇鏇 (齋憲選夢醖鏇繭鏇繭願, 0.79) 更多